Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice
Adama Kamagate, Shen Qu, German Perdomo, Dongming Su, Dae Hyun Kim, Sandra Slusher, Marcia Meseck, H. Henry Dong
Adama Kamagate, Shen Qu, German Perdomo, Dongming Su, Dae Hyun Kim, Sandra Slusher, Marcia Meseck, H. Henry Dong
View: Text | PDF
Research Article

FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice

  • Text
  • PDF
Abstract

Excessive production of triglyceride-rich VLDL is attributable to hypertriglyceridemia. VLDL production is facilitated by microsomal triglyceride transfer protein (MTP) in a rate-limiting step that is regulated by insulin. To characterize the underlying mechanism, we studied hepatic MTP regulation by forkhead box O1 (FoxO1), a transcription factor that plays a key role in hepatic insulin signaling. In HepG2 cells, MTP expression was induced by FoxO1 and inhibited by exposure to insulin. This effect correlated with the ability of FoxO1 to bind and stimulate MTP promoter activity. Deletion or mutation of the FoxO1 target site within the MTP promoter disabled FoxO1 binding and resulted in abolition of insulin-dependent regulation of MTP expression. We generated mice that expressed a constitutively active FoxO1 transgene and found that increased FoxO1 activity was associated with enhanced MTP expression, augmented VLDL production, and elevated plasma triglyceride levels. In contrast, RNAi-mediated silencing of hepatic FoxO1 was associated with reduced MTP and VLDL production in adult mice. Furthermore, we found that hepatic FoxO1 abundance and MTP production were increased in mice with abnormal triglyceride metabolism. These data suggest that FoxO1 mediates insulin regulation of MTP production and that augmented MTP levels may be a causative factor for VLDL overproduction and hypertriglyceridemia in diabetes.

Authors

Adama Kamagate, Shen Qu, German Perdomo, Dongming Su, Dae Hyun Kim, Sandra Slusher, Marcia Meseck, H. Henry Dong

×

Figure 10

Effect of FoxO1 knockdown on hepatic metabolism in FoxO1 transgenic mice.

Options: View larger image (or click on image) Download as PowerPoint
Effect of FoxO1 knockdown on hepatic metabolism in FoxO1 transgenic mice...
Male FoxO1S253A transgenic mice at 4 months of age were stratified by body weight and randomly assigned to 2 groups (n = 8), which were intravenously injected with FoxO1-RNAi or scrambled RNAi vector at 1.5 × 1011 pfu/kg body weight. (A) Fasting blood glucose levels. (B) Hepatic FoxO1 protein levels. (C) Fasting plasma insulin levels. (D) Plasma TG levels after intravenous administration of tyloxapol. (E) Hepatic VLDL production rates. (F) Plasma apoB secretion. Aliquots of plasma (20 μg protein) 80 min after tyloxapol injection were analyzed by semiquantitative western blot assay using anti-apoB antibody. (G) Hepatic MTP protein levels. (H) Fasting plasma TG levels. (I) Hepatic TG levels. (J) Fasting plasma NEFA levels. (K) Fasting plasma cholesterol levels. (L) Body weight. All data were obtained between 4 and 8 days from mice fasted for 24 h after vector administration. *P < 0.05 versus control.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts